{"entity":{"id":"nct06764628","kind":"trial","name":"A Study of SHR-4375 in Subjects With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-4375 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Study of SHR-4375 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT06764628 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 208 participants planned, started 2025-01-09 and due to reach its primary completion in 2027-05. Interventions recorded: SHR-4375.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06764628","url":"https://clinicaltrials.gov/study/NCT06764628"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06764628","phase":"1/2","setting":"An Open-label, Single-arm, Multicenter Phase I/II Clinical Study of SHR-4375 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":208,"outcomes":[]},"route":"/trials/nct06764628/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}